U.S. Markets closed

Eli Lilly and Company (LLY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
84.75+0.52 (+0.62%)
At close: 4:04PM EDT

84.75 0.00 (0.00%)
After hours: 6:12PM EDT

People also watch
Full screen
Previous Close84.23
Bid0.00 x
Ask0.00 x
Day's Range84.41 - 85.12
52 Week Range64.18 - 86.72
Avg. Volume3,566,233
Market Cap89.15B
PE Ratio (TTM)40.98
Earnings DateN/A
Dividend & Yield2.08 (2.49%)
Ex-Dividend Date2017-08-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com4 hours ago

    5 New Breast Cancer Treatments That Are Helping to Save Lives

    In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.

  • Reuters10 hours ago

    FDA tentatively approves Merck's copycat of Sanofi's Lantus

    Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.

  • Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?
    Zacks2 days ago

    Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?

    Eli Lilly and Company's (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.